Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: Is there room for novel anti-angiogenetic treatments?

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 1, 2007, Pages 145-150

  Calabro L ^a   Di Giacomo, A M ^a   Altomonte, M ^a   Fonsatti, E ^a   Mazzei, M A ^a   Volterrani, L ^a   Miracco, C ^a   Maio, Michele ^a,b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Angiogenesis; CD105; Endoglin; Epithelioid hemangioendothelioma; Interferon alpha

Indexed keywords

ALPHA2A INTERFERON; ENDOGLIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD EXAMINATION; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHEMICAL ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEMANGIOENDOTHELIOMA; HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; LUNG METASTASIS; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN METASTASIS; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD34; FEMALE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2A; LIVER NEOPLASMS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34247504023     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Uchimura K., Nakamuta M., Osoegawa M. et al.: Hepatic epithelioid hemangioendothelioma. J. Clin. Gastroenterol. 32: 431-434, 2001.
2. Lauffer J.M., Zimmermann A., Krahenbuhl L., Triller J., Baer H.U.: Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. Cancer 78: 2318-2327, 1996.
3. Makhlouf H., Ishak K.G. and Goodman Z.D.: Epithelioid hemangioendothelioma of the liver a clinicopathologic study of 137 cases. Cancer 3: 562, 1999.
4. Ishak K.G., Sesterhenn I.A., Goodman Z.D.: Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum. Pathol. 15: 839-852, 1984.
5. Ben-Haim M., Roavaie S., Ye M.Q. et al.: Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl. Surg. 5: 526-531, 1999.
6. Kemeny M.M.: Hepatic resection when, what kind, and for which patients. J. Surg. Oncol. (suppl) p. 54, 1991.
7. Marino I., Todo S., Tzakis A. et al.: Treatment of hepatic hemangioendothelioma with liver transplantation. Cancer 62: 2079, 1988.
8. Kayler L.K., Merion R.M., Areneas J.D. et al.: Epitelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2b. Transplantation 74: 128-130, 2002.
9. D'Annibale M., Piovanello P., Carlini P. et al.: Epithelioid hemangioendothelioma of the liver: case report and review of the literature. Transplant. Proc. 34: 1248, 2002.
10. Madariaga J., Marino I., Karavias I.: Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann. Surg. Oncol. 2: 483, 1995.
11. Holley M., Cuschieri A.: Epithelioid hemangioendothelioma of the liver: objective response to hepatic intra-arterial 5-FU. Eur. J. Surg. Oncol. 15: 73, 1989.
12. Corbella F., Arico M., Podesta A.F. et al.: Infantile hepatic hemangioendothelioma treated by radiotherapy. Pediatr. Radiol. 13: 297-300, 1983.
13. Peter S.D., Moss A.A., Huettl E.A. et al.: Chemoembolization followed by orthotopic liver transplant for epithelioid hemangioendothelioma. Clin. Transplant. 17: 549-553, 2003.
14. Galvao F.H.F., Bakonyi-Neto A., Machado M.A.C. et al.: Interferon alpha-2B and liver resection to treat multifocal hepatic epithelioid hemangioendothelioma: a relevant approach to avoid liver transplantation. Transplantation Proc. 37: 4354-4358, 2005.
15. Makhlouf H., Ishak K.G., Goodman Z.D.: Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 3: 562, 1999.
16. Mascarenhas R.C.V., Sanghvi A.N., Friedlander L., Geyer S.J., Beasley H.S., Von Thiel D.H.: Thalidomide inhibits the growth and progression of hepatic epitelioid hemangioendothelioma. Oncology 67: 471-475, 2004.
17. Alomari A.: The lollipop sign: a new cross-sectional sign of hepatic epithelioid hemangioendothelioma. Eur. J. Radiol. April 24, 2006.
18. Oleszak E., Inglot A.D.: Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular actin of interferon in synchronized mouse or human cells. J. Interferon Res. 1: 37-48, 1980.
19. Compagni A., Wilgenbus P., Impagnatiello M.A. et al.: Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60: 7163-7169, 2000.
20. Roudier-Pujol C., Lacronique J., Guillemette J. et al.: Multifocal epithelioid hemangioendothelioma with partial remission after interferon-2a treatment. Ann. Dermatol. Venereol. 121: 898-904, 1994.
21. Burrows F.J., Derbyshire E.J., Tazzari P.L. et. al.: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1: 1623-1634, 1995.
22. Li C., Hampson I.N., Kumar P., Bernabeu C., Kumar S.: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells, FASEB J. 14: 55-64, 2000.
23. Fonsatti E., Altomonte M., Nicotra M.R., Natali P.G., Maio M.: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 22: 6557-6563, 2003.
24. Fonsatti E., Maio M.: Highlights on endoglin (CD105): from findings towards clinical applications in human cancer. J. Transl. Med. 2: 18, 2004
25. Fonsatti E., Jekunen A.P., Kairemo K.J. et al: Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res. 6: 2037-2043, 2000.
26. Adams G.P., Weiner L.M.: Monoclonal therapy of cancer. Natl. Biotechnol. 23: 1147-1157, 2005.
27. Harris M.: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5: 292-302, 2004.
28. Shiozaki K., Harada N., Greco W.R. et. al.: Antiangiogenetic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol. Immunother. 55: 140-150, 2006.